[CAS NO. 301326-22-7] CH-223191

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [301326-22-7]

Catelog

SLK-S7711

Brand

Selleck

CAS

301326-22-7

DESCRIPTION [301326-22-7]

Overview

MDL	MFCD00377884
Molecular Weight	333.39
Molecular Formula	C19H19N5O
SMILES	O=C(C1=CC=NN1C)NC2=CC=C(N=NC3=CC=CC=C3C)C=C2C

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	2.9995 mL	14.9975 mL	29.9949 mL
5 mM	0.5999 mL	2.9995 mL	5.9990 mL
10 mM	0.2999 mL	1.4997 mL	2.9995 mL
50 mM	0.0600 mL	0.2999 mL	0.5999 mL

Description

CH-223191 is a potent and specific antagonist with of 30 nM.

Targets

AhR ^[1]
(in HepG2 cells)

30 nM

In vitro

CH-223191 blocks TCDD-mediated nuclear translocation and DNA binding of AhR, and also causes the inhibition of TCDD-induced cytochrome P450 enzyme activity. In human glioblastoma cells, CH-223191downregulates the TGF-beta/Smad pathway, and reduces clonogenic survival and invasiveness. In SK-N-SH human-derived neuronal cells, CH223191 counteracts the TCDD-induced suppression of neuronal acetylcholinesterase expression. In endothelial cells, CH-223191 potentiates ICAM-1 expression and prevents RelB nuclear translocation.

References

[1] Kim SH, et al. Mol Pharmacol. 2006, 69(6), 1871-1878.
[2] Gramatzki D, et al. Oncogene. 2009, 28(28), 2593-2605.
[3] Xie HQ, et al. Environ Health Perspect. 2013, 121(5), 613-618.
[4] de Souza AR, et al. Toxicol Sci. 2014, 140(1), 204-223.